abstract |
The present invention relates to the fields of medicine and biotechnology. In particular, the present invention relates to novel antisense oligonucleotides (AON) that can be used in the treatment, prevention and / or delay of Stargardt's disease and / or ABCA4-related eye diseases. More particularly, the invention relates to AONs used to inhibit or block exon 39 skipping in human ABCA4 pre-mRNA. |